Jazz Buys Compliance Trouble With FazaClo Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The schizophrenia drug’s previous owner, Azur Pharma, produced a patient brochure that drew a warning letter FDA’s Office of Prescription Drug Promotion.
You may also be interested in...
Teva Cited For Promo Suggesting 14-Year Old Schizophrenia Study Shows Clozapine Superiority
FDA says Teva’s promotional piece misleadingly implies clozapine is superior to olanzapine, risperidone and haloperidol in improving one symptom cluster.
‘Tis The Season… For An FDA Enforcement Letter To Alcon
The eighth enforcement letter from FDA in a decade cites the company for unjustified claims about its seasonal allergic rhinitis drug, Patanase.
Jazz Cools On Women’s Health, Sells Unit To Meda
The sale of an asset portfolio that includes Elsetrin for hot flashes could give Jazz the financial flexibility for another product acquisition.